Please login to the form below

Not currently logged in

Roche files patent lawsuit against Teva for osteoporosis drug

Roche files a lawsuit against generic manufacturer Teva over an alleged patent violation on its osteoporosis treatment, Boniva

Swiss pharmaceutical company Roche has filed a lawsuit against Israel-headquartered generic manufacturer Teva over an alleged patent violation on its osteoporosis treatment Boniva (ibandronate).

A Roche spokesperson said the lawsuit was instituted to prevent Teva from marketing a generic version of Boniva 150 mg tablets. The basic patent runs until 2012, with further patents protecting the drug until 2023.

Boniva recorded sales of CHF 374m (USD 315.7m) in H1 FY07, according to Roche.

30th September 2008


Featured jobs

Subscribe to our email news alerts


Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....